Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

From Point to Filament Defects in Hybrid Nematic Films.

Chiccoli C, Pasini P, Zannoni C, Skačej G, Yoshida H, Hiroshima T, Sunami K, Ouchi T, Ozaki M.

Sci Rep. 2019 Nov 29;9(1):17941. doi: 10.1038/s41598-019-50948-w.

2.

Topological charge transport by mobile dielectric-ferroelectric domain walls.

Takehara R, Sunami K, Miyagawa K, Miyamoto T, Okamoto H, Horiuchi S, Kato R, Kanoda K.

Sci Adv. 2019 Nov 15;5(11):eaax8720. doi: 10.1126/sciadv.aax8720. eCollection 2019 Nov.

3.

Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.

Hirose S, Murakami N, Takahashi K, Kuno I, Takayanagi D, Asami Y, Matsuda M, Shimada Y, Yamano S, Sunami K, Yoshida K, Honda T, Nakahara T, Watanabe T, Komatsu M, Hamamoto R, Kato MK, Matsumoto K, Okuma K, Kuroda T, Okamoto A, Itami J, Kohno T, Kato T, Shiraishi K, Yoshida H.

Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31606-3. doi: 10.1016/j.ygyno.2019.10.022. [Epub ahead of print]

PMID:
31757465
4.

[Diffuse large B-cell lymphoma relapsing with intravascular large B-cell lymphoma-like perivascular and intravascular lesions].

Ishikawa T, Fukumi T, Moriyama T, Murakami H, Nagakita K, Yoshioka T, Makita M, Shinno Y, Sunami K.

Rinsho Ketsueki. 2019;60(10):1455-1461. doi: 10.11406/rinketsu.60.1455. Japanese.

PMID:
31695007
5.

Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.

Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H.

Hematol Oncol. 2019 Oct 31. doi: 10.1002/hon.2688. [Epub ahead of print]

PMID:
31674032
6.

Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.

Sugiura I, Suzuki K, Ri M, Chou T, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Iida S.

Int J Hematol. 2019 Oct 29. doi: 10.1007/s12185-019-02754-3. [Epub ahead of print]

PMID:
31664647
7.

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study.

Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M; CD5+ DLBCL Treatment Study Group.

Haematologica. 2019 Oct 24. pii: haematol.2019.231076. doi: 10.3324/haematol.2019.231076. [Epub ahead of print]

8.

Topologically Protected Generation of Stable Wall Loops in Nematic Liquid Crystals.

Ouchi T, Imamura K, Sunami K, Yoshida H, Ozaki M.

Phys Rev Lett. 2019 Aug 30;123(9):097801. doi: 10.1103/PhysRevLett.123.097801.

PMID:
31524469
9.

Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis.

Yokota Y, Yoshioka T, Senoh M, Sunami K.

BMJ Case Rep. 2019 Aug 15;12(8). pii: e228427. doi: 10.1136/bcr-2018-228427.

10.

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study.

Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Tobinai K.

Cancer Sci. 2019 Sep;110(9):2924-2932. doi: 10.1111/cas.14139. Epub 2019 Aug 10.

11.

Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.

Suzuki K, Doki N, Meguro K, Sunami K, Kosugi H, Sasaki O, Takagi T, Murakami H, Shimizu K.

Int J Hematol. 2019 Oct;110(4):447-457. doi: 10.1007/s12185-019-02700-3. Epub 2019 Jul 19.

PMID:
31325152
12.

Decrease in number of mast cells in resected nasal polyps as an indicator for postoperative recurrence of chronic rhinosinusitis.

Teranishi Y, Jin D, Takano S, Sunami K, Takai S.

Immun Inflamm Dis. 2019 Sep;7(3):191-200. doi: 10.1002/iid3.261. Epub 2019 Jun 17.

13.

Feasibility of genomic profiling with next-generation sequencing using specimens obtained by image-guided percutaneous needle biopsy.

Sone M, Arai Y, Sugawara S, Kubo T, Itou C, Hasegawa T, Umakoshi N, Yamamoto N, Sunami K, Hiraoka N, Kubo T.

Ups J Med Sci. 2019 Apr;124(2):119-124. doi: 10.1080/03009734.2019.1607635.

14.

[The Role of Core Hospitals and Cooperative Hospitals for Cancer Genomic Medicine in Japan].

Sunami K.

Gan To Kagaku Ryoho. 2019 Apr;46(4):617-621. Japanese.

PMID:
31164495
15.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators.

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

PMID:
31097405
16.

Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K.

Ann Hematol. 2019 Jul;98(7):1703-1711. doi: 10.1007/s00277-019-03702-1. Epub 2019 May 2.

PMID:
31049648
17.

Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).

Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.

Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1.

PMID:
30937622
18.

Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.

Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.

Bone Marrow Transplant. 2019 Oct;54(10):1595-1604. doi: 10.1038/s41409-019-0478-4. Epub 2019 Feb 19.

PMID:
30783208
19.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.

Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2.

20.

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.

Abe Y, Sunami K, Yamashita T, Ueda M, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K.

Oncotarget. 2019 Jan 15;10(5):595-605. doi: 10.18632/oncotarget.26562. eCollection 2019 Jan 15.

21.

[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].

Iida S, Izumi T, Aotsuka N, Komeno T, Ishida T, Sunami K, Handa H, Berg D, Kase Y, Soeda J.

Rinsho Ketsueki. 2018;59(11):2399-2407. doi: 10.11406/rinketsu.59.2399. Japanese.

PMID:
30531133
22.

Evidence for solitonic spin excitations from a charge-lattice-coupled ferroelectric order.

Sunami K, Nishikawa T, Miyagawa K, Horiuchi S, Kato R, Miyamoto T, Okamoto H, Kanoda K.

Sci Adv. 2018 Nov 30;4(11):eaau7725. doi: 10.1126/sciadv.aau7725. eCollection 2018 Nov.

23.

Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.

Takamatsu H, Yamashita T, Kurahashi S, Saitoh T, Kondo T, Maeda T, Nakazawa H, Murata M, Narita T, Kuroda J, Hashimoto H, Kawamura K, Miyamoto T, Honda S, Ichinohe T, Atsuta Y, Sunami K.

Biol Blood Marrow Transplant. 2019 Mar;25(3):474-479. doi: 10.1016/j.bbmt.2018.11.003. Epub 2018 Nov 10.

PMID:
30423479
24.

Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT).

Int J Hematol. 2019 Jan;109(1):131. doi: 10.1007/s12185-018-2557-5.

PMID:
30406327
25.

A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT).

Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Erratum in: Int J Hematol. 2018 Nov 7;:.

PMID:
30284685
26.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

27.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

PMID:
30176173
28.

A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing.

Kato M, Nakamura H, Nagai M, Kubo T, Elzawahry A, Totoki Y, Tanabe Y, Furukawa E, Miyamoto J, Sakamoto H, Matsumoto S, Sunami K, Arai Y, Suzuki Y, Yoshida T, Tsuchihara K, Tamura K, Yamamoto N, Ichikawa H, Kohno T, Shibata T.

Genome Med. 2018 Jun 7;10(1):44. doi: 10.1186/s13073-018-0547-0.

29.

Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults.

Suzuki Y, Yano T, Suehiro Y, Iwasaki H, Hidaka M, Otsuka M, Sunami K, Inoue N, Sawamura M, Ito T, Iida H, Nagai H.

Int J Hematol. 2018 Aug;108(2):161-166. doi: 10.1007/s12185-018-2449-8. Epub 2018 Mar 31.

PMID:
29605873
30.

Primary adenocarcinoma of the trachea revealing a mucinous bronchial gland cell origin.

Miura A, Mori T, Yoshida A, Watanabe Y, Sunami K, Watanabe S, Kohno T, Tsuta K.

Pathol Res Pract. 2018 May;214(5):796-799. doi: 10.1016/j.prp.2018.03.006. Epub 2018 Mar 6. No abstract available.

PMID:
29549985
31.

Shape control of surface-stabilized disclination loops in nematic liquid crystals.

Sunami K, Imamura K, Ouchi T, Yoshida H, Ozaki M.

Phys Rev E. 2018 Feb;97(2-1):020701. doi: 10.1103/PhysRevE.97.020701.

PMID:
29548110
32.

Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.

Muta T, Miyamoto T, Kamimura T, Kanda Y, Nohgawa M, Ueda Y, Iwato K, Sasaki O, Mori T, Uchida N, Iida S, Fukuda T, Atsuta Y, Sunami K.

Acta Haematol. 2018;139(1):35-44. doi: 10.1159/000484652. Epub 2018 Jan 17.

PMID:
29339642
33.

Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan.

Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Aoyama T, Sugimori H, Komatsu N.

Blood Cancer J. 2017 Nov 23;7(12):631. doi: 10.1038/s41408-017-0002-2. No abstract available.

34.

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.

Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, Sunami K, Masunari T, Nawa Y, Yamane H, Gomyo H, Takahashi T, Yano T, Matsuo K, Ohshima K, Nakamura S, Yoshino T, Tanimoto M.

Haematologica. 2017 Dec;102(12):2097-2103. doi: 10.3324/haematol.2017.167742. Epub 2017 Sep 29.

35.

The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.

Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Takahashi H, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Nakajima H, Miura I, Takeuchi K.

Leuk Lymphoma. 2018 Jan;59(1):97-104. doi: 10.1080/10428194.2017.1330541. Epub 2017 Jun 8.

PMID:
28593796
36.

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.

Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2017 Oct;106(4):562-572. doi: 10.1007/s12185-017-2255-8. Epub 2017 May 19.

PMID:
28527129
37.

Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.

Nagai H, Shimomura T, Takeuchi M, Hanada S, Komeno T, Sunami K, Hidaka M, Yano T, Kitano K, Yoshida I, Inoue N, Saito A, Horibe K, Motitani S, Ichihara S, Watanabe T, Sawamura M.

Leuk Lymphoma. 2017 Dec;58(12):2845-2851. doi: 10.1080/10428194.2017.1319054. Epub 2017 May 16.

PMID:
28509595
38.

A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.

Miura K, Konishi J, Miyake T, Makita M, Hojo A, Masaki Y, Uno M, Ozaki J, Yoshida C, Niiya D, Kitazume K, Maeda Y, Takizawa J, Sakai R, Yano T, Yamamoto K, Sunami K, Hiramatsu Y, Aoyama K, Tsujimura H, Murakami J, Hatta Y, Kanno M.

Oncologist. 2017 May;22(5):554-560. doi: 10.1634/theoncologist.2016-0260. Epub 2017 Apr 13.

39.

Acute Bilateral Photoreceptor Degeneration in an Infant After Vaccination Against Measles and Rubella.

Kuniyoshi K, Hatsukawa Y, Kimura S, Fujino T, Ohguro H, Nakai R, Sunami K, Mishima SI, Sato T, Kusaka S, Suzuki Y, Shimomura Y.

JAMA Ophthalmol. 2017 May 1;135(5):478-482. doi: 10.1001/jamaophthalmol.2017.0380.

40.

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, Matsue K, Miyoshi M, Bleickardt E, Matsumoto M, Taniwaki M.

Blood Cancer J. 2017 Mar 10;7(3):e540. doi: 10.1038/bcj.2017.18. No abstract available.

41.

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.

Suzuki K, Ri M, Chou T, Sugiura I, Takezako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Ota K, Iida S.

Cancer Sci. 2017 Mar;108(3):461-468. doi: 10.1111/cas.13166.

42.

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.

Okuma HS, Horinouchi H, Kitahara S, Asao T, Sunami K, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y.

Clin Lung Cancer. 2017 Mar;18(2):234-240.e2. doi: 10.1016/j.cllc.2016.09.005. Epub 2016 Oct 25.

43.

Treatment strategy in untreated transplant-eligible multiple myeloma patients.

Sunami K.

Rinsho Ketsueki. 2016;57(10):2064-2073. Review. Japanese.

PMID:
27795516
44.

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T.

Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.

45.

Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma.

Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, Kunitoh H, Matsumoto S, Takano A, Shimizu K, Goto A, Tsuta K, Watanabe SI, Ohe Y, Watanabe Y, Goto Y, Nokihara H, Furuta K, Yoshida A, Goto K, Hishida T, Tsuboi M, Tsuchihara K, Miyagi Y, Nakayama H, Yokose T, Tanaka K, Nagashima T, Ohtaki Y, Maeda D, Imai K, Minamiya Y, Sakamoto H, Saito A, Shimada Y, Sunami K, Saito M, Inazawa J, Nakamura Y, Yoshida T, Yokota J, Matsuda F, Matsuo K, Daigo Y, Kubo M, Kohno T.

Nat Commun. 2016 Aug 9;7:12451. doi: 10.1038/ncomms12451.

46.

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).

Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, Eto T, Tsuda H, Fujisaki T, Miyamoto T, Tsuneyoshi N, Iyama S, Nagafuji K, Harada M.

Int J Hematol. 2016 Jun;103(6):676-85. doi: 10.1007/s12185-016-1976-4. Epub 2016 Mar 21.

PMID:
27084252
47.

Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).

Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K.

Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5.

PMID:
27044390
48.

Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.

Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, Ohashi K, Kubonishi S, Fukuda T, Ito T, Tomita N, Ichinohe T, Kato K, Morishima Y, Atsuta Y, Sunami K, Kanda Y.

Leuk Lymphoma. 2016 Sep;57(9):2077-83. doi: 10.3109/10428194.2016.1154958. Epub 2016 Mar 9.

PMID:
26961137
49.

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.

Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y.

Lung Cancer. 2016 Mar;93:77-81. doi: 10.1016/j.lungcan.2016.01.004. Epub 2016 Jan 11.

PMID:
26898618
50.

Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.

Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, Saito M, Nokihara H, Watanabe S, Ohe Y, Kohno T.

J Thorac Oncol. 2016 Feb;11(2):203-12. doi: 10.1016/j.jtho.2015.10.005. Epub 2015 Dec 19.

Supplemental Content

Loading ...
Support Center